Long-Term Survival (23 Years) in a 26-Year-old Male after Antineoplaston Therapy for a Progressive, Diffuse Intrinsic Pontine Glioma: A Case Report

Burzynski Stanislaw R,Janicki Tomasz,Beenken Samuel,Burzynski Gregory S

doi:10.23937/2469-5866/1410038

Abstract

Individuals suffering from diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis with a median overall survival of approximately 11 months, and a 2-year survival rate of 10%. Long-term survival is very rare. To date, radiotherapy remains the standard of care at diagnosis, but offers a survival benefit of approximately 3 months. Chemotherapy has not shown to be effective. There is no Standard of Care for progressive DIPG after radiation therapy (RT). The purpose of this case report is to present the 23-year survival of a 26-year-old male treated with Antineoplaston therapy A10 and AS2-1 (ANP) for progressive DIPG.

Highlights

Diffuse intrinsic pontine glioma (DIPG) originates in the glial cells of the pons, an integral part of the brainstem
We present the case of a young male who developed a persistent complete response (CR) following Antineoplaston Therapy (ANP)
Individuals suffering from diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis with a median overall survival of approximately 11 months, and a 2 year survival rate of 10% [1,2]

Summary

Introduction

Diffuse intrinsic pontine glioma (DIPG) originates in the glial cells of the pons, an integral part of the brainstem. Individuals suffering from DIPG face a dismal prognosis with a median overall survival of approximately 11 months, and a 2 year survival rate of 10% [1,2]. Individuals suffering from diffuse intrinsic pontine glioma (DIPG) face a dismal prognosis with a median overall survival of approximately 11 months, and a 2-year survival rate of 10%. Radiotherapy remains the standard of care at diagnosis, but offers a survival benefit of approximately 3 months. There is no Standard of Care for progressive DIPG after radiation therapy (RT). The purpose of this case report is to present the 23-year survival of a 26-year-old male treated with Antineoplaston therapy A10 and AS2-1 (ANP) for progressive DIPG

Methods

Results

Conclusion